scholarly journals Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation

Author(s):  
Ramona A. Silvestre ◽  
Alejandro Almería Lafuente ◽  
Lucía Jiménez-Mendiguchía ◽  
Ana García-Cano ◽  
Rubén Romero López ◽  
...  

Abstract Objectives Graves’ disease is secondary to the presence of anti-thyrotropin receptor antibodies (TRAb), which stimulate thyroid hormones. TRab determination is crucial for etiological diagnosis. The objectives of this study were (i) to compare two methods for determining TRab by chemoluminiscence vs. standard TRACE-immunofluorescence; (ii) to determine the diagnostic validity of the three methods. Methods A retrospective study in 194 patients with a TRAb determination request. TRAb were determined by immunofluorescence (Kryptor, ThermoFisher) and chemiluminescence (Immulite, Siemens and Maglumi, Snibe). Clinical validation: medical records were reviewed and categorized according to thyroid function. Statistical analysis: Differences in quantitative variables were assessed by intraclass correlation coefficient, Bland–Altman plot, and mean differences (mD). Qualitative variables were dichotomized by cut-off points; Kappa coefficient was calculated. Correlations were evaluated by Pearson’s coefficient and Passing-Bablok regression analysis. The diagnostic validity of the three methods was investigated. Results Kryptor-Immulite: mD: 1.2 (95%CI: −16 to >18). Passing-Bablok: Constant error (95%CI: −0.8349 to −0.5987). Proportional error (95%CI: 0.7862–1.0387). ICC: 0.86 (95%CI: 0.82–0.89). Kappa coefficient: 0.68 (95%CI 0.59–0.78). Kryptor-Maglumi: mD: −0.3 (95%CI: −12 to >12). Passing-Bablok: Constant error (95%CI: −0.7701 to >0.1621. Proportional error (95%CI: 0.8571 to 1.3179. ICC: 0.93 (95%CI: 0.89–0.97). Kappa coefficient: 0.53 (95%CI: 0.32–0.74). Diagnosis of Graves’ disease was confirmed in 113 patients (Kryptorf showed better specificity and positive predictive value, whereas Immulite demonstrated better sensitivity and negative predictive value). Conclusions The three methods have a good diagnostic performance for Graves’ disease, with superimposable results on Bland–Altman plot. Interchangeability was not confirmed on the regression and agreement analysis, with the presence of biases.

2019 ◽  
Vol 105 (4) ◽  
pp. e1006-e1014 ◽  
Author(s):  
George J Kahaly ◽  
Tanja Diana ◽  
Michael Kanitz ◽  
Lara Frommer ◽  
Paul D Olivo

Abstract Context Scarce data exist regarding the relevance of stimulatory (TSAb) and blocking (TBAb) thyrotropin receptor antibodies in the management of Graves disease (GD). Objective To evaluate the clinical utility and predictive value of TSAb/TBAb. Design Prospective 2-year trial. Setting Academic tertiary referral center. Patients One hundred consecutive, untreated, hyperthyroid GD patients. Methods TSAb was reported as percentage of specimen-to-reference ratio (SRR) (cutoff SRR < 140%). Blocking activity was defined as percent inhibition of luciferase expression relative to induction with bovine thyrotropin (TSH, thyroid stimulating hormone) alone (cutoff > 40% inhibition). Main Outcome Measures Response versus nonresponse to a 24-week methimazole (MMI) treatment defined as biochemical euthyroidism versus persistent hyperthyroidism at week 24 and/or relapse at weeks 36, 48, and 96. Results Forty-four patients responded to MMI, of whom 43% had Graves orbitopathy (GO), while 56 were nonresponders (66% with GO; P < 0.01). At baseline, undiluted serum TSAb but not thyroid binding inhibitory immunoglobulins (TBII) differentiated between thyroidal GD-only versus GD + GO (P < 0.001). Furthermore, at baseline, responders demonstrated marked differences in diluted TSAb titers compared with nonresponders (P < 0.001). During treatment, serum TSAb levels decreased markedly in responders (P < 0.001) but increased in nonresponders (P < 0.01). In contrast, TBII strongly decreased in nonresponders (P = 0.002). All nonresponders and/or those who relapsed during 72-week follow-up period were TSAb-positive at week 24. A shift from TSAb to TBAb was noted in 8 patients during treatment and/or follow-up and led to remission. Conclusions Serum TSAb levels mirror severity of GD. Their increase during MMI treatment is a marker for ongoing disease activity. TSAb dilution analysis had additional predictive value.


1999 ◽  
Vol 84 (1) ◽  
pp. 90-97 ◽  
Author(s):  
Sabine Costagliola ◽  
Nils G. Morgenthaler ◽  
Rudolf Hoermann ◽  
Klaus Badenhoop ◽  
Joachim Struck ◽  
...  

Thyroid ◽  
2000 ◽  
Vol 10 (7) ◽  
pp. 579-586 ◽  
Author(s):  
Won Bae Kim ◽  
Hyun Kyung Chung ◽  
Young Joo Park ◽  
Do Joon Park ◽  
Kazuo Tahara ◽  
...  

1997 ◽  
Vol 82 (9) ◽  
pp. 2926-2930 ◽  
Author(s):  
Birte Nygaard ◽  
Jens Helmer Knudsen ◽  
Laszlo Hegedüs ◽  
Annegrete Veje Cand Scient ◽  
Jens Erik Mølholm Hansen

Sign in / Sign up

Export Citation Format

Share Document